Lupin gets USFDA nod for generic Firdapse tablets

in Limited (LUPIN) is in focus on November 3 after receiving USFDA approval for Amifampridine Tablets, 10 mg, a generic version of Firdapse. The approval was announced after market hours on November 2. The drug treats a rare condition that causes muscle weakness. Lupin was one of the first companies to file for this generic, so it is eligible for 180 days of shared generic exclusivity in the US. The exclusivity period is the key positive. Early entry lets Lupin sell the generic before most competitors arrive, which usually means better pricing and margins in the first six months. It also strengthens Lupin’s specialty generics portfolio in the US. Investors should keep expectations measured. The exclusivity is shared with other first filers, so Lupin will not have the market to itself. The company has not disclosed a launch date, pricing or expected revenue. The real value depends on how quickly Lupin launches and how many rivals share the window. Investors should watch the launch timeline, the number of competing generics, US sales trends, and Q2 FY27 results. The key question is whether this approval adds meaningfully to US revenue or remains a small, short-lived opportunity. Disclosure: I do not hold any position in Lupin Limited. This post is for informational purposes only and is not investment advice.